OralParenteralDosed ingredientTherapeutic flag Cosmetic cross-reference

Sodium Phosphate, Dibasic, Anhydrous

CAS 7558-79-4

Sodium Phosphate, Dibasic, Anhydrous (CAS 7558-79-4) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 61 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
3
SOURCE DrugCentral
Adverse signals
61
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Sodium Phosphate, Dibasic, Anhydrous
CAS Number
7558-79-4
UNII
22ADO53M6F
InChIKey
BNIILDVGGAEEIG-UHFFFAOYSA-L
ChEMBL ID
CHEMBL1060
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
DISODIUM PHOSPHATESODIUM PHOSPHATE, DIBASIC ANHYDROUS
dosed ingredientoralparenteraltherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1060 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- EC50 32000 nM 1 -
- Ki 9800 nM 1 -
Carbonic anhydrase 4
Enzyme
 Ki 5.01 - Homo sapiens
SOURCE DrugCentral 61 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Appendicolith 56 171.563 10074458
Aplastic anaemia 55 124.782 10002967
Appendicitis 57 120.033 10003011
Cardiogenic shock 62 98.574 10007625
Ventricular fibrillation 50 80.829 10047290
Cytokine release syndrome 50 77.588 10052015
Abdominal distension 88 76.432 10000060
Lymphocyte count decreased 53 68.232 10025256
Blood phosphorus increased 29 63.264 10050196
Intestinal pseudo-obstruction 20 62.828 10022698
Ascites 63 61.678 10003445
Sepsis 122 59.787 10040047
Hypogonadism 17 53.821 10058359
Multiple organ dysfunction syndrome 71 53.581 10077361
Stress 60 52.662 10042209
Vomiting 199 46.788 10047700
Abdominal pain 135 45.849 10000081
Incision site pain 16 45.443 10058043
Hyponatraemia 77 41.313 10021036
Acute phosphate nephropathy 7 38.429 10069688
Drug ineffective 76 36.701 10013709
Myasthenia gravis 20 35.286 10028417
Red blood cells urine positive 15 34.163 10038182
Hypophosphataemia 25 33.66 10021058
Blood albumin decreased 26 32.131 10005287
Blood uric acid increased 20 30.29 10005861
Mucosal inflammation 44 29.919 10028116
Blood urea increased 33 28.199 10005851
Joint swelling 7 25.815 10023232
Protein urine present 15 22.495 10053123
Loss of bladder sensation 5 22.195 10070632
Mutism 9 22.008 10028403
Febrile neutropenia 73 21.756 10016288
General physical health deterioration 83 20.968 10049438
Diarrhoea 204 20.821 10012735
Neutrophil count increased 22 20.22 10029368
Product compounding quality issue 4 19.499 10069329
Neutropenic sepsis 21 19.446 10049151
Food refusal 6 19.409 10080283
Nausea 214 19.38 10028813
Blood phosphorus decreased 12 19.258 10049471
Intestinal obstruction 27 19.083 10022687
Encephalopathy 31 18.019 10014625
Hypokalaemia 49 17.694 10021015
Back pain 87 17.3 10003988
Herpes zoster reactivation 5 17.254 10080516
Nephrocalcinosis 7 17.249 10029146
Systemic lupus erythematosus 3 17.05 10042945
Dry mouth 38 16.62 10013781
Drug interaction 17 16.274 10013710

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 9 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
DISODIUM PHOSPHATE 236719 SU MTHSPL
Sodium phosphate, Dibasic, Anhydrous 314838 SU MTHSPL
SODIUM PHOSPHATE, DIBASIC ANHYDROUS 314838 SU MTHSPL
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 314838 SU MTHSPL
Sodium Phosphate, Dibasic Anhydrous 314838 SU MTHSPL
Sodium Phosphate, Dibasic, Anhydrous 314838 SU MTHSPL
sodium phosphate, dibasic, anhydrous 314838 SU MTHSPL
Sodium phosphate, dibasic, anhydrous 314838 SU MTHSPL
sodium phosphate, dibasic, anhydrous 314838 PIN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Sodium Phosphate, Dibasic, Anhydrous used for in pharmaceutical contexts?

Sodium Phosphate, Dibasic, Anhydrous (CAS 7558-79-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Sodium Phosphate, Dibasic, Anhydrous?

Sodium Phosphate, Dibasic, Anhydrous has 61 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Aplastic anaemia, Appendicitis, Cardiogenic shock, Ventricular fibrillation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Sodium Phosphate, Dibasic, Anhydrous also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Disodium Phosphate with EU status "permitted".

What clinical phase is Sodium Phosphate, Dibasic, Anhydrous in?

Sodium Phosphate, Dibasic, Anhydrous is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Sodium Phosphate, Dibasic, Anhydrous?

Sodium Phosphate, Dibasic, Anhydrous has 3 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 4.